Court Denies Kenvue Rehearing, Reviving 500 Tylenol Autism Suits
KVUE sits 34% above its 52-week low of $14.02.
Summary
The 2nd US Circuit Court of Appeals rejected Kenvue's request to reconsider or rehear en banc the July panel ruling that revived roughly 500 lawsuits alleging Tylenol use during pregnancy causes autism and ADHD. That ruling found the district judge improperly excluded expert testimony from three doctors backing the parents' claims. This follows the September 11 petition Kenvue and major pharmacy chains filed challenging the July 13 panel decision — that effort has now failed. The exposure is real: the litigation had been dormant and is now live again, with the appellate route largely exhausted and a Supreme Court appeal the remaining option. It lands while the $40B Kimberly-Clark acquisition is in its final regulatory stretch, and a revived mass-tort overhang is exactly the kind of contingent liability that complicates deal closing and valuation.
At the time of this announcement, KVUE was trading at $18.75 on NYSE in the Life Sciences sector, with a market capitalization of approximately $36.3B. The 52-week trading range was $14.02 to $20.13. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.